期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 38, 期 3, 页码 171-175出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1040-8428(01)00097-X
关键词
intraperitoneal chemotherapy; ovarian cancer; cisplatin; paclitaxel; carboplatin
The intraperitoneal administration of antineoplastic agents in the front-line treatment of advanced ovarian cancer is a rational strategy, based on anatomic and pharmacokinetic considerations, as well as an understanding of the natural history of the malignancy. Phase 1 and 2 clinical trial data have supported the potential role for this unique method of drug delivery as a safe and effective management approach in this clinical setting. Two randomized phase 3 trials have demonstrated a favorable impact of cisplatin-based front-line intraperitoneal therapy on survival for patients with 'optimal residual' advanced ovarian cancer. However, for several reasons, additional investigative efforts are required to convince oncologists the time, effort and potential toxicity of intraperitoneal therapy justify its routine use as initial therapy of this malignancy. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据